OBJECTIVES: National societies provide little guidance regarding which colonoscopy bowel preps are best tolerated and most effective; this reflects a lack of comparative effectiveness studies that directly evaluate the available preps in a "real-world" setting. To address this gap, we conducted a prospective, commercially unfunded comparative effectiveness study of currently available bowel preps and measured their impact on bowel cleansing. METHODS: We included patients aged ≥18 years, who presented for an outpatient colonoscopy at a large medical center serving more than 70 academic and community-based endoscopists who are free to prescribe the bowel prep of their choice. The primary outcome was bowel cleansing quality as measured by the Boston Bowel Preparation Scale. We performed regression models with random effects on the outcomes to adjust for confounding. RESULTS: Approximately 4,339 colonoscopies were performed by 75 endoscopists. Magnesium citrate, MiraLAX with Gatorade, MoviPrep, OsmoPrep, Prepopik/Clenpiq, and Suprep all had significantly higher prep tolerability compared with GoLYTELY (all P < 0.05). For bowel cleansing, Suprep (7.28 ± 1.66; P < 0.001), MoviPrep (7.11 ± 1.62; P = 0.004), and MiraLAX with Gatorade (7.09 ± 1.64; P < 0.001) had higher total Boston Bowel Preparation Scale scores compared with GoLYTELY (6.67 ± 1.87); there were no significant differences among the remaining preps. Split-prep dosing was associated with better cleansing; however, men, opioid and tricyclic antidepressent users, and patients with diabetes and cirrhosis had worse cleansing (all P < 0.05). CONCLUSIONS: In this prospective, real-world comparative effectiveness study of available bowel preps, we found that MiraLAX with Gatorade, MoviPrep, and Suprep were prospectively associated with superior tolerability and bowel cleansing.
OBJECTIVES: National societies provide little guidance regarding which colonoscopy bowel preps are best tolerated and most effective; this reflects a lack of comparative effectiveness studies that directly evaluate the available preps in a "real-world" setting. To address this gap, we conducted a prospective, commercially unfunded comparative effectiveness study of currently available bowel preps and measured their impact on bowel cleansing. METHODS: We included patients aged ≥18 years, who presented for an outpatient colonoscopy at a large medical center serving more than 70 academic and community-based endoscopists who are free to prescribe the bowel prep of their choice. The primary outcome was bowel cleansing quality as measured by the Boston Bowel Preparation Scale. We performed regression models with random effects on the outcomes to adjust for confounding. RESULTS: Approximately 4,339 colonoscopies were performed by 75 endoscopists. Magnesium citrate, MiraLAX with Gatorade, MoviPrep, OsmoPrep, Prepopik/Clenpiq, and Suprep all had significantly higher prep tolerability compared with GoLYTELY (all P < 0.05). For bowel cleansing, Suprep (7.28 ± 1.66; P < 0.001), MoviPrep (7.11 ± 1.62; P = 0.004), and MiraLAX with Gatorade (7.09 ± 1.64; P < 0.001) had higher total Boston Bowel Preparation Scale scores compared with GoLYTELY (6.67 ± 1.87); there were no significant differences among the remaining preps. Split-prep dosing was associated with better cleansing; however, men, opioid and tricyclic antidepressent users, and patients with diabetes and cirrhosis had worse cleansing (all P < 0.05). CONCLUSIONS: In this prospective, real-world comparative effectiveness study of available bowel preps, we found that MiraLAX with Gatorade, MoviPrep, and Suprep were prospectively associated with superior tolerability and bowel cleansing.
Authors: Laura C Seeff; Thomas B Richards; Jean A Shapiro; Marion R Nadel; Diane L Manninen; Leslie S Given; Fred B Dong; Linda D Winges; Matthew T McKenna Journal: Gastroenterology Date: 2004-12 Impact factor: 22.682
Authors: Reena V Chokshi; Christine E Hovis; Thomas Hollander; Dayna S Early; Jean S Wang Journal: Gastrointest Endosc Date: 2012-02-28 Impact factor: 9.427
Authors: Brennan M R Spiegel; Jennifer Talley; Paul Shekelle; Nikhil Agarwal; Bradley Snyder; Roger Bolus; Nicole Kurzbard; Michael Chan; Andrew Ho; Marc Kaneshiro; Kristina Cordasco; Hartley Cohen Journal: Am J Gastroenterol Date: 2011-04-12 Impact factor: 10.864
Authors: Vincent K Dik; Leon M G Moons; Melek Hüyük; Peter van der Schaar; Wouter H de Vos Tot Nederveen Cappel; Pieter C J Ter Borg; Maarten A C Meijssen; Rob J T H Ouwendijk; Doris M Le Fèvre; Merijn Stouten; Onno van der Galiën; Theo J Hiemstra; Jan F Monkelbaan; Martijn G H van Oijen; Peter D Siersema Journal: Gastrointest Endosc Date: 2015-01-17 Impact factor: 9.427
Authors: Edwin J Lai; Audrey H Calderwood; Gheorghe Doros; Oren K Fix; Brian C Jacobson Journal: Gastrointest Endosc Date: 2009-01-10 Impact factor: 9.427
Authors: Patricia V Hernandez; Jennifer L Horsley-Silva; Diana L Snyder; Noemi Baffy; Mary Atia; Laura Koepke; Matthew R Buras; Elisabeth S Lim; Kevin Ruff; Sarah B Umar; Sameer Islam; Francisco C Ramirez Journal: BMC Gastroenterol Date: 2020-07-13 Impact factor: 3.067
Authors: Joseph G H Lee; Jennifer J Telford; Cherry Galorport; Jordan Yonge; Christopher A Macdonnell; Robert A Enns Journal: J Can Assoc Gastroenterol Date: 2020-09-16
Authors: Klaus Gottlieb; Marco Daperno; Keith Usiskin; Bruce E Sands; Harris Ahmad; Colin W Howden; William Karnes; Young S Oh; Irene Modesto; Colleen Marano; Ryan William Stidham; Walter Reinisch Journal: Gut Date: 2020-07-22 Impact factor: 23.059